Nanoparticle Immunotherapy for Lung Cancer
Official title: Advancing the commercialization readiness of nanoparticle-based immunotherapy for cancer treatment
Funded at Pdx Pharmaceuticals, INC. · NIH-11184418 · Data updated 2026-11-12
This project is developing a new nanoparticle-based immunotherapy called ARAC-02 to improve outcomes for people with non-small cell lung cancer.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Pdx Pharmaceuticals, INC. NIH-funded |
| Lab location | 1 site (Portland, UNITED STATES) |
| Project start | September 5, 2024 |
| Project end | August 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $89,348 |
| NIH project number | 5SB1CA287735-02 |
| Project ID | NIH-11184418 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with non-small cell lung cancer who have not responded well to current immune checkpoint inhibitors or are seeking new treatment approaches might be ideal candidates for future clinical trials.
✕Less likely to help
Patients without non-small cell lung cancer or those whose cancer does not involve the specific immune pathways targeted by ARAC-02 may not receive direct benefit from this particular therapy.
What this research studies
For patients with non-small cell lung cancer, current treatments often involve harsh drugs and radiation, with limited long-term success. This project focuses on ARAC-02, a new type of immunotherapy that uses tiny nanoparticles to deliver multiple agents directly to cancer cells. These nanoparticles are designed to kill cancer cells, release signals that activate the immune system, and block proteins that prevent the immune system from fighting the tumor. The goal is to create a powerful anti-tumor immune response that could lead to better results than existing therapies.
Why it matters
Potential benefit: If successful, this new immunotherapy could offer a more effective and potentially curative treatment option for many patients with non-small cell lung cancer.
How similar studies have gone: This approach builds on prior successful research, including a highly-rated initial grant phase, published data in Nature Communications, and a US patent for the ARAC-02 technology.
Where this research is happening
-
Pdx Pharmaceuticals, INC.
Portland, United States Active
Researchers
- Principal investigator: Ngamcherdtrakul, Worapol — Pdx Pharmaceuticals, INC.
- Study coordinator: Ngamcherdtrakul, Worapol
Related research
Other NIH-funded projects on the same topics.
-
Boosting immune response to fight cancer
This study is exploring a new way to help your immune system better fight cancer by tweaking certain cells in your body, and it aims to improve treatment for people with advanced cancer.
-
A center focused on immunotherapy for pediatric cancers.
This study is exploring new ways to use the body's immune system to fight childhood cancers, aiming to create better treatments for kids whose cancers haven't responded well to standard therapies.
-
Algorithms to find HLA-E neoantigens for cancer immunotherapy
Aims to develop computer methods to discover tumor-specific targets presented by HLA-E to guide new T cell therapies for cancer.
-
Immunotherapy for glioblastoma: advancing treatment and understanding
A patient-friendly summary of a grant exploring new immune-based treatments for glioblastoma to improve options for people affected by this brain cancer.
-
How CRISPR-based gene activation could shape immunotherapy responses in clear cell cancers
A research project at Stanford is using CRISPR-based gene activation to understand why some clear cell ovarian and kidney cancers respond to immunotherapy while others do not.
-
Hybrid biomaterial system to boost immunotherapy for rheumatoid arthritis
A new, patient-facing immunotherapy approach uses specialized particles to retrain the immune system to calm RA in adults.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.